Corbus Pharmaceuticals Holdings, Inc. (CRBP) key performance indicators and operating metrics (11 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Incidence of Alopecia Treatment-Related Adverse Events | 25.60 percent | FY2026-Q1 |
| Incidence of Dysgeusia Treatment-Related Adverse Events | 19.90 percent | FY2026-Q1 |
| Incidence of Fatigue Treatment-Related Adverse Events | 22.40 percent | FY2026-Q1 |
| Incidence of Grade 3 Treatment-Related Adverse Events | 19.20 percent | FY2026-Q1 |
| Incidence of Keratitis Treatment-Related Adverse Events | 49.20 percent | FY2026-Q1 |
| Incidence of Peripheral Neuropathy | 7.30 percent | FY2026-Q1 |
| Number of Patients in Safety Population | 317.00 | FY2026-Q1 |
| Treatment Discontinuations Related to CRB-701 | 2.80 percent | FY2026-Q1 |
| Objective Response Rate for Locally Advanced or Metastatic Urothelial Cancer at 3.6 Milligrams per Kilogram | 55.60 percent | FY2025-Q4 |
| Unconfirmed Objective Response Rate for Cervical Cancer at 3.6 Milligrams per Kilogram | 37.50 percent | FY2025-Q4 |
| Unconfirmed Objective Response Rate for Head and Neck Squamous Cell Carcinoma at 3.6 Milligrams per Kilogram | 47.60 percent | FY2025-Q4 |
Back to CRBP overview · CRBP earnings · CRBP holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.